NAS:CRIS (USA)
Business Description
Curis Inc
NAICS : 325414
SIC : 2836
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Description
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 32.05 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -10.22 | |||||
| Beneish M-Score | -3.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -28.3 | |||||
| 3-Year EBITDA Growth Rate | 19.7 | |||||
| 3-Year EPS without NRI Growth Rate | 20.1 | |||||
| 3-Year FCF Growth Rate | 23.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 1.85 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.93 | |||||
| 9-Day RSI | 41.14 | |||||
| 14-Day RSI | 44.53 | |||||
| 6-1 Month Momentum % | -66.45 | |||||
| 12-1 Month Momentum % | -85.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.02 | |||||
| Quick Ratio | 13.02 | |||||
| Cash Ratio | 12.45 | |||||
| Days Sales Outstanding | 88.88 | |||||
| Days Payable | 3128.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.19 | |||||
| Operating Margin % | -460.2 | |||||
| Net Margin % | -490.81 | |||||
| ROE % | -51.21 | |||||
| ROA % | -30.47 | |||||
| ROIC % | -151.56 | |||||
| ROC (Joel Greenblatt) % | -752.66 | |||||
| ROCE % | -29.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.77 | |||||
| PB Ratio | 1.21 | |||||
| Price-to-Tangible-Book | 1.37 | |||||
| EV-to-EBIT | 0.53 | |||||
| EV-to-EBITDA | 0.53 | |||||
| EV-to-Revenue | -2.38 | |||||
| EV-to-Forward-Revenue | 0.21 | |||||
| EV-to-FCF | 0.61 | |||||
| Price-to-Median-PS-Value | 0.54 | |||||
| Price-to-Net-Current-Asset-Value | 1.49 | |||||
| Price-to-Net-Cash | 1.64 | |||||
| Earnings Yield (Greenblatt) % | 188.68 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CRIS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.517 | ||
| EPS (TTM) ($) | -0.57 | ||
| Beta | 2.81 | ||
| Volatility % | 83.61 | ||
| 14-Day RSI | 44.53 | ||
| 14-Day ATR ($) | 0.100089 | ||
| 20-Day SMA ($) | 1.10573 | ||
| 12-1 Month Momentum % | -85.66 | ||
| 52-Week Range ($) | 0.7 - 9.04 | ||
| Shares Outstanding (Mil) | 91.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Curis Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||